Lilly Picks Paul’s Brain: CNS Researcher To Succeed R&D Head Watanabe
Executive Summary
Lilly R&D president-elect Steven Paul, MD, will bring an extensive background in central nervous system discovery and research to Lilly's top research position
You may also be interested in...
Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities
Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy
Lilly Elevates Santini To Senior VP; “Access & Policy” Are Priorities
Lilly is placing additional emphasis on prescription drug access and pricing issues with the appointment of U.S. Operations President Gino Santini to senior VP-corporate strategy and policy
Lilly R&D personnel changes
Leader of Lilly's Zyprexa product team and clinical research fellow Alan Breier, MD, assumes Chief Medical Officer and VP-Medical position; Breier replaces Michael McDonald, MD, who is leaving Lilly. VP-Clinical Research and U.S. Regulatory Affairs and Policy Tim Franson, MD, replaces Michael Clayman, MD, as VP-Global Regulatory Affairs; Clayman moves into the new position of VP-Lilly Research Laboratories. Breier and Franson report to Steven Paul, MD, recently appointed R&D president (1"The Pink Sheet" May 19, 2003, p. 16)...